Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Last trade$4.53
Day change+$0.135 (+3.08%)
Day range$4.33 – $4.69
Volume103,792
Market cap$480M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$480.49M
Price / earnings
—
Price / book
4.45×
Price / sales
3.95×
EV / sales
3.6×
EV / EBITDA
-20.13×
Profitability
Earnings per share
-$0.24
Return on assets
-12.98%
Return on equity
-24.2%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.32×
Quick ratio
3.89×
Cash ratio
1.46×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GYRE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$32.93M
$29.11M
$22.52M
$37.2M
$32.69M
$29.73M
$22.06M
$27.87M
Cost of revenue
$1.95M
$2.21M
$1.23M
$1.74M
$1.63M
$1.15M
$894K
$1.18M
Gross profit
$30.99M
$26.9M
$21.29M
$35.45M
$31.07M
$28.58M
$21.16M
$26.7M
Selling, general and administrative
$23.95M
$21.62M
$21.36M
$30.52M
$21.78M
$22.47M
$15.8M
$22.32M
Research and development
$8.51M
$19.14M
$6.74M
$4.82M
$7.8M
$8.35M
$3.1M
$3.71M
Total operating expenses
$32.51M
$41.26M
$30.65M
$35.33M
$29.57M
$30.82M
$18.89M
$26.03M
Operating income
-$1.52M
-$14.36M
-$9.36M
$120K
$1.49M
-$2.24M
$2.27M
$663K
Interest expense
$0
$0
$0
$1.75M
$0
$0
$0
$1.55M
Income before taxes
-$1.75M
-$14.43M
-$9.24M
-$66K
$2.52M
-$1.58M
$4.64M
$772K
Income taxes
$733K
-$164K
$621K
$1.3M
$593K
$662K
$901K
$203K
Net income
-$2.48M
-$14.27M
-$9.86M
-$1.37M
$1.93M
-$2.24M
$3.73M
$569K
Net income attributable to common shareholders
-$4.05M
-$11.66M
-$8.69M
-$1.72M
$1.03M
-$2.04M
$2.7M
-$99K
EBITDA
-$1.05M
-$12.88M
-$8.68M
$815K
$2.32M
-$1.23M
$2.81M
$1.16M
Basic earnings per share
-$0.04
-$0.12
-$0.10
-$0.02
$0.01
-$0.02
$0.03
$0.00
Diluted earnings per share
-$0.04
-$0.12
-$0.10
-$0.01
$0.01
-$0.03
$0.03
$0.00
Recent news
Company coverage with links to the original publishers.
Gyre Therapeutics reported Q3 2026 earnings of $0.04 per share, beating consensus estimates of a $0.15 loss, with revenues of $32.93 million exceeding expectations by 15.15%. However, the stock has declined 37.1% year-to-date versus the S&P 500's 12.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Gyre Therapeutics has completed its all-stock acquisition of Cullgen Inc. for approximately $300 million, creating a fully integrated biopharmaceutical company with U.S. and China operations. The combined entity will have a commercial-stage product (ETUARY® for lung fibrosis) and a robust pipeline focused on fibrosis and inflammatory diseases, including the lead candidate F351 for liver fibrosis. Dr. Ying Luo, former CEO of Cullgen, becomes President and CEO of the combined company.
Gyre Therapeutics reported full-year 2025 revenue of $116.6 million, up 10% year-over-year, within guidance. The company achieved alignment with China's CDE on conditional approval pathway for Hydronidone with NDA submission expected in H1 2026. Gyre completed enrollment in a Phase 3 pirfenidone pneumoconiosis trial and announced an agreement to acquire Cullgen for approximately $300 million to expand its targeted protein degradation platform. However, 2026 revenue guidance of $100.5-$111.0 million represents a 4.8-13.8% decline, reflecting a transition period prioritizing regulatory activities.
Gyre Therapeutics reported Q3 2025 net income of $5.9 million, with quarterly revenue of $30.6 million, up 20% year-over-year. The company revised full-year revenue guidance to $115-118 million due to delayed product rollouts and procurement uncertainties.
Gyre Therapeutics will present positive Phase 3 clinical trial results for Hydronidone, a novel anti-fibrotic agent targeting liver fibrosis in chronic hepatitis B, at AASLD's The Liver Meeting® 2025 in Washington D.C.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jan 13, 2023
$0.24
Jan 12, 2023
special
Sep 21, 2022
$0.715
Sep 20, 2022
special
Aug 20, 2015
$4.269
Aug 19, 2015
special
Stock splits
Historical share-structure events and their execution dates.